SCHEMBL6038430

SCHEMBL6038430

CC(C)c1ccc(S(=O)(=O)Nc2ncc(Br)nc2OCc2ccccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 15/20 0.60
EDNRA P25101 3/20 0.47
AR P10275 1/20 0.44
CCR5 P51681 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6039315 0.91 CCR4 (0.60) CCR4EDNRAARCCR5
SCHEMBL6038742 0.89 CCR4 (0.71) CCR4EDNRAAR
SCHEMBL6038861 0.88 CCR4 (0.64) CCR4EDNRAAR
SCHEMBL6039073 0.88 CCR4 (0.64) CCR4EDNRAAR
SCHEMBL6039161 0.88 CCR4 (0.63) CCR4EDNRAAR
SCHEMBL6038517 0.88 CCR4 (0.58) CCR4EDNRAAR
SCHEMBL6039187 0.87 CCR4 (0.63) CCR4EDNRAAR
SCHEMBL6038965 0.86 CCR4 (0.68) CCR4EDNRAARCCR5
SCHEMBL6038713 0.86 CCR4 (0.61) CCR4EDNRAAR
SCHEMBL6039156 0.85 CCR4 (0.60) CCR4EDNRAAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 CCR4 1/4885EDNRA 512/4885AR 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.